Neuroprotective effects of erythropoietin in acute ischemic stroke

International Journal of Preventive Medicine

Volumn 4, Issue , 2013, Pages S306-S312

  Asadi, Bahador ^a   Askari, Gholam Reza ^b   Khorvash, Fariborz ^b   Bagherpur, Ali ^b   Mehrabi, Farzad ^a   Karimi, Mohammad ^b   Ghasemi, Majid ^c   Najjaran, Abolfazl ^b  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Erythropoietin; National institutes of health stroke scale; Neuroprotection; Stroke

Indexed keywords

ERYTHROPOIETIN;

ADULT; AGED; ARM MOVEMENT; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; LANGUAGE; LEG MOVEMENT; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSATION; TREATMENT OUTCOME;

EID: 84975299187     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S. Acute ischemic stroke update. Pharmacotherapy 2010;30:493-514.
2. Wang JK, Portbury S, Thomas MB, Barney S, Ricca DJ, Morris DL, et al. Cardiac glycosides provide neuroprotection against ischemic stroke: Discovery by a brain slice-based compound screening platform. Proc Natl Acad Sci USA 2006;103:10461-6.
3. Sallar AM, Williams PB, Omishakin AM, Lloyd DP. Stroke prevention: Awareness of risk factors for stroke among African American residents in the Mississippi delta region. J Natl Med Assoc 2010;102:84-94.
4. Writing Group for the American Academy of Neurology, AANS/CNS Cerebrovascular Section, Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology, Meyers PM, Schumacher HC, et al. Performance and training standards for endovascular ischemic stroke treatment. AJNR Am J Neuroradiol 2010;31:E8-11.
5. Meyers PM, Schumacher HC, Alexander MJ, Derdeyn CP, Furlan AJ, Higashida RT, et al. Performance and training standards for endovascular ischemic stroke treatment. J Neurosurg 2010;113:149-52.
6. Flemming KD, Brown RD Jr. Secondary prevention strategies in ischemic stroke: Identification and optimal management of modifiable risk factors. Mayo Clin Proc 2004;79:1330-40.
7. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, et al. Transient ischemic attack-Proposal for a new definition. N Engl J Med 2002;347:1713-6.
8. Caplan LR. Transient ischemic attack: Definition and natural history. Curr Atheroscler Rep 2006;8:276-80.
9. Landau WM. Causes of stroke. Ann Neurol 1992;32:596-7.
10. Park SH, Jung JM. Risk factors for acute cardioembolic brain stroke in acute myocardial infarction. Korean Circ J 2005;35:353-6.
11. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: The atherosclerosis risk in communities study. Stroke 2006;37:2493-8.
12. Ong TZ, Raymond AA. Risk factors for stroke and predictors of one-month mortality. Singapore Med J 2002;43:517-21.
13. Marwat MA, Usman M, Hussain M. Stroke and its relationship between to risk factors. Gomal J Med Sci 2009;7:17-20.
14. Bilić I, Dzamonja G, Lusić I, Matijaca M, Caljkusić K. Risk factors and outcome differences between ischemic and hemorrhagic stroke. Acta Clin Croat 2009;48:399-403.
15. thed. New York: Mc Graw Hill; 2005. p. 285.
16. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-7.
17. th Virtual Congress of Cardiology-QVCC. Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland. Available from: http://www.fac.org.ar/qcvc/llave/c126i/lewartowski. php [Last Cited 2013 Jan 20].
18. Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000;343:710-22.
19. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000;31:77-81.
20. Wolf-Dieter H. Systemic rtPA in Patients with Acute Ischemic Stroke. Max-Planck-Institut für neurologische Forschung, Köln, Germany. Emergency treatment for a stroke. BMJ Publishing Group Limited; 2009.
21. Liu XB, Wang JA, Yu SP, Keogh CL, Wei L. Therapeutic strategy of erythropoietin in neurological disorders. CNS Neurol Disord Drug Targets 2008;7:227-34.
22. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006;26:1269-74.
23. Ntaios G, Savopoulos C, Chatzinikolaou A, Hatzitolios AI. The neuroprotective role of erythropoietin in the management of acute ischaemic stroke: From bench to bedside. Acta Neurol Scand 2008;118:362-6.
24. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008;59:22-33.
25. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795-803.
26. Lapchak PA, Kirkeby A, Zivin JA, Sager TN. Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 2008;1238:208-14.
27. Zhang W, Sun B, Yu Z, An J, Liu Q, Ren T. High dose erythropoietin promotes functional recovery of rats following facial nerve crush. J Clin Neurosci 2009;16:554-6.
28. Lykissas MG, Sakellariou E, Vekris MD, Kontogeorgakos VA, Batistatou AK, Mitsionis GI, et al. Axonal regeneration stimulated by erythropoietin: An experimental study in rats. J Neurosci Methods 2007;164:107-15.
29. Kalialis LV, Olsen NV. Erythropoietin-A new therapy in cerebral ischemia? Ugeskr Laeger 2003;165:2477-81.
30. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010;41:1008-12.
31. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:647-56.
32. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.